Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review

Upadacitinib is a selective Janus kinase inhibitor approved for the treatment of severe atopic dermatitis (AD). This systematic review aims to summarize the most recent data in terms of effectiveness and safety of upadacitinib in the treatment of severe AD in a real-world setting. The review include...

Full description

Saved in:
Bibliographic Details
Published in:Clinical, cosmetic and investigational dermatology cosmetic and investigational dermatology, 2024-01, Vol.17, p.593-604
Main Authors: Ibba, Luciano, Gargiulo, Luigi, Vignoli, Carlo Alberto, Fiorillo, Giovanni, Valenti, Mario, Costanzo, Antonio, Narcisi, Alessandra
Format: Article
Language:English
Subjects:
Advertising executives
Atopic dermatitis
Care and treatment
jaki
Pharmaceutical industry
real-life
systematic review
upadacitinib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Upadacitinib is a selective Janus kinase inhibitor approved for the treatment of severe atopic dermatitis (AD). This systematic review aims to summarize the most recent data in terms of effectiveness and safety of upadacitinib in the treatment of severe AD in a real-world setting. The review included a comprehensive search of databases, including PubMed, Google Scholar and Web of Science, according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. The literature search initially identified 242 studies. Of these, 214 were excluded after reviewing their titles and abstracts. We then conducted a full-text review of 25 studies, of which 17 met our inclusion criteria and were therefore included in our systematic review. The analysis of real-world studies showed high effectiveness of upadacitinib, in terms of both clinical signs and subjective symptoms, in different patient populations, including those resistant to other treatments. No new significant safety concerns have emerged as compared to randomized clinical trials.
ISSN:1178-7015
1178-7015
DOI:10.2147/CCID.S329442